PRME Stock — Prime Medicine Inc.: Cash, EV, Pipeline

Share price

$3.12

Market cap

$565.9M

Cash

$95.1M

Enterprise value

$470.8M

Balance sheet

Cash	$95.1M
Debt	$0.0M
Net cash	$95.1M
Enterprise value	$470.8M
Basic shares	180.7M shares
Fully diluted shares	215.8M shares
Fully diluted market cap	$673.4M
Cash per share	$0.53

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PRME daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2028 - Jan 24, 2029	PM577a	Phase 2	Wilson Disease; Wilson's Disease; Wilsons Disease	—
Feb 12 - Mar 26	PM359	Phase 2	Chronic Granulomatous Disease; Granulomatous Disease, Chronic	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PM359

Phase 1 · Active Modality: ex vivo prime editing (autologous HSCT)

Target NCF1

Indications

Chronic granulomatous disease (CGD) (Phase 1)

Catalysts

— H1 2027

Status note Ex vivo Prime Editing for CGD correcting the ΔGT mutation in NCF1. Phase 1/2 ongoing in patients undergoing autologous hematopoietic stem cell transplantation; RMAT designation granted Jun 2026.

PM577a

Phase 1 · Active Modality: in vivo prime editor (LNP-delivered)

Aliases PM577

Target ATP7B

Indications

Wilson disease (H1069Q) (Phase 1)

Catalysts

— 2027

Status note Lead in vivo program. CTA cleared in New Zealand (Jun 2026) and IND cleared by FDA (Jul 2026); global Phase 1/2 trial initiating. Follow-on editors for additional ATP7B mutations in development.

PM647

Preclinical · Active Modality: in vivo prime editor (LNP-delivered)

Target SERPINA1

Indications

Alpha-1 antitrypsin deficiency (AATD) (Preclinical)

Catalysts

— Q3 2026
— 2027

Status note In vivo program for AATD; IND application submission and/or CTA filing on track for Q3 2026. (Jul 2026 arbitration: Tribunal confirmed PM647 is within the company's field under the Beam Collaboration Agreement.)

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PM577a
Lead indication	Wilson Disease
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07748403	Phase 2	Recruiting	Sponsor	PRME	—	Wilson Disease; Wilson's Disease; Wilsons Disease	—
NCT06559176	Phase 2	Enrolling by invitation	Sponsor	PRME	—	Chronic Granulomatous Disease; Granulomatous Disease, Chronic	—
NCT07226622	Not disclosed	Active, not recruiting	Sponsor	PRME	—	Wilson Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Prime Medicine, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	1,997,552	+24,270	0.35%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

PRME — Prime Medicine Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders